Omentin-1 vs Efinopegdutide
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Efinopegdutide |
|---|---|---|
| Category | Diabetes & Metabolic | Weight Management |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | ~35 kDa | N/A |
| Half-Life | hours | Approximately 1 week |
| Amino Acids | 313 | N/A |
| Typical Dose | No approved human dose; research use only | Trial-dependent; weekly SC dosing |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 14 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Efinopegdutide Benefits
- ✓reduced body weight
- ✓improved insulin sensitivity
- ✓reduced liver fat
- ✓greater satiety
Omentin-1 Dosing
not established|not established
Efinopegdutide Dosing
once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Efinopegdutide Side Effects
- ⚠nausea
- ⚠decreased appetite
- ⚠fatigue
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Efinopegdutide
Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.